Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.49 USD | -2.59% | +8.40% | +4.93% |
03-13 | Top Premarket Decliners | MT |
03-12 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Evolution of the average Target Price on iTeos Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering iTeos Therapeutics, Inc.
JPMorgan Chase | |
Wedbush | |
HC Wainwright | |
Piper Sandler | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- ITOS Stock
- Consensus iTeos Therapeutics, Inc.